The coronavirus vaccine from the American biotechnology company Novavax was effective against the original version of COVID-19 and against the British strain. This is stated in a statement by the company, RIA Novosti reports.
It is noted that the drug showed an effectiveness of 96.4 percent against the original version of the coronavirus and 86.3 percent against the British. The company also said that when it comes to severe illness, the drug is 100 percent effective.
The third phase of the NVX CoV2373 vaccine trial took place in the UK. The study covered more than 15 thousand participants aged 18 to 84, 27 percent of them were over 65 years old.
There are currently several COVID-19 vaccines in the world. So, in Russia, in addition to “Sputnik V”, there are also registered “EpiVacCorona” from the center “Vector” and “KoviVak” from the center named after Chumakov. In the United States and the United Kingdom, they began to inoculate the population with the drug from Pfizer / BioNTech. In addition, the US authorities have approved the vaccine for Moderna and Johnson & Johnson.
